Saad kenderian
@kenderian_ss
Hematology, Bone Marrow Transplantation, Immunotherapy, CART cell therapy, Mayo Clinic, Rochester, MN
ID: 4498029973
08-12-2015 15:25:15
557 Tweet
996 Followers
303 Following
Read the new InFocus article by @Carlhjune and Marco Ruella— CAR T cell resistance to oncogenic transformation. bit.ly/3V0sRXR Penn Medicine
Dr. Saad kenderian explains the ongoing research taking place to potentially move #CARTCellTherapy into earlier lines of therapy for patients with chronic lymphocytic #leukemia. Via OncLive.com: bit.ly/3wNG6So
Drs. Saad kenderian and John Copland are collaborating across Mayo Clinic Comprehensive Cancer Center sites as principal investigators researching #CARTCellTherapy for solid #ThyroidCancer tumors. To drive this promising therapy closer to patients, they're addressing four hurdles: mayocl.in/3ySpGIQ
Mayo Clinic Allison Garda Shaji Kumar Judy Boughey 1–1:30 p.m.: Meet hematologist/oncologist and lymphoproliferative diseases expert Dr. Paul Hampel at Booth No. 27104. Paul Hampel #ASCO24
The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor Center for Cell and Gene Therapy and still remains in remission. We need more of these stories. researchsquare.com/article/rs-423…
Saad kenderian Mayo Clinic U.S. FDA 💡If you want to learn more on CAR-MSC please read CAR-MSC article on Nature Biomedical Engineering by Olivia Sirpilla in Saad kenderian's lab at Mayo Clinic Rochester: 📚pubmed.ncbi.nlm.nih.gov/38561490/ 🔗isctglobal.org/telegrafthub/b…
Look forward to moving this technology to the clinic Mayo Clinic MayoRegMed Mayo Clinic Comprehensive Cancer Center Olivia Sirpilla
Congrats to the now Dr. Ruchi Patel for the publication of her PhD thesis in Science Immunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. Penn Medicine Ruella Lab science.org/doi/10.1126/sc…
The Mayo Clinic research of Saad kenderian published in Nature Communications uses CRISPR gene-editing technology to understand why #CAR-T cell therapy fails in some patients and identifies strategies for success. mayocl.in/3Xih0Em
#Regenmed immunotherapy research of Saad kenderian has identified a new reason CAR-T cell therapy fails in some cancer patients. A new paper explores whether CRISPR gene editing and monoclonal antibodies could improve the chances for success. Learn more: mayocl.in/3TuR7Ae
IL-4 drives exhaustion of CD8+ CART cells Nature Communications Saad kenderian nature.com/articles/s4146…
The team of Mayo Clinic @Kenderian_SS has discovered a new reason #CAR-T cell therapy fails in some patients and new strategies to try to overcome it. This paper is making news in Latin America. bit.ly/3XLHob0
A Mayo Clinic leukemia patient had exhausted all treatment options when he participated in a clinical trial for #CAR-T cell therapy. The findings of the Saad kenderian study, published in a paper, show why the patient has new hope. mayocl.in/47AtFaw
The Mayo Clinic research of Saad kenderian published in Nature Communications uses CRISPR gene-editing technology to understand why #CAR-T cell therapy fails in some patients and identifies strategies for success. mayocl.in/3ZQyCu1
.Mayo Clinic #Regenmed immunotherapy research of Saad kenderian has identified a new reason #CAR-T cell therapy fails in some cancer patients. A new paper explores whether CRISPR gene editing and monoclonal antibodies could improve the chances for success. mayocl.in/3YFcqkp
